298 related articles for article (PubMed ID: 17440059)
81. Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer.
Xu L; Qin Y; Huang J; Qin J; Gu J; Zhu H; Liu H; Cai Y; Wu X; Feng J
Anticancer Drugs; 2013 Apr; 24(4):406-14. PubMed ID: 23411684
[TBL] [Abstract][Full Text] [Related]
82. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek).
Hay RV; Cao B; Skinner RS; Su Y; Zhao P; Gustafson MF; Qian CN; Teh BT; Knudsen BS; Resau JH; Shen S; Waters DJ; Gross MD; Vande Woude GF
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7064s-7069s. PubMed ID: 16203803
[TBL] [Abstract][Full Text] [Related]
83. PHA665752 inhibits the HGF-stimulated migration and invasion of cells by blocking PI3K/AKT pathway in uveal melanoma.
Wang Z; He C; Liu L; Ma N; Chen X; Zheng D; Qiu GH
Neoplasma; 2017; 64(3):377-388. PubMed ID: 28253717
[TBL] [Abstract][Full Text] [Related]
84. MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks.
Medová M; Aebersold DM; Zimmer Y
Int J Cancer; 2012 Feb; 130(3):728-34. PubMed ID: 21400509
[TBL] [Abstract][Full Text] [Related]
85. [Vascular growth and non-small cell lung cancer].
Fan X; Guo X; Han B
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Aug; 24(8):499-502. PubMed ID: 11718044
[No Abstract] [Full Text] [Related]
86. [bcl-2 expression in small cell lung cancer: a mechanism for apoptosis antagonism and immune evasion].
Zheng JM; Wang DK; Jiang HM
Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1537-9. PubMed ID: 16361157
[TBL] [Abstract][Full Text] [Related]
87. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
Sasaki T; Tanno S; Shibukawa K; Osanai S; Kawabe J; Ohsaki Y
Int J Oncol; 2008 Sep; 33(3):525-32. PubMed ID: 18695882
[TBL] [Abstract][Full Text] [Related]
88. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.
Pezzella F; Pastorino U; Tagliabue E; Andreola S; Sozzi G; Gasparini G; Menard S; Gatter KC; Harris AL; Fox S; Buyse M; Pilotti S; Pierotti M; Rilke F
Am J Pathol; 1997 Nov; 151(5):1417-23. PubMed ID: 9358768
[TBL] [Abstract][Full Text] [Related]
89. Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.
Ai J; Chen Y; Peng X; Ji Y; Xi Y; Shen Y; Yang X; Su Y; Sun Y; Gao Y; Ma Y; Xiong B; Shen J; Ding J; Geng M
Mol Cancer Ther; 2018 Apr; 17(4):751-762. PubMed ID: 29237805
[TBL] [Abstract][Full Text] [Related]
90. Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
Jiang Y; Allen D; Kersemans V; Devery AM; Bokobza SM; Smart S; Ryan AJ
Lung Cancer; 2015 Nov; 90(2):191-8. PubMed ID: 26323213
[TBL] [Abstract][Full Text] [Related]
91. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Su Y; Ortiz J; Liu S; Bugge TH; Singh R; Leppla SH; Frankel AE
Cancer Res; 2007 Apr; 67(7):3329-36. PubMed ID: 17409442
[TBL] [Abstract][Full Text] [Related]
92. Malignant transformation of host cells by a human small cell lung cancer xenografted into nude mice.
Soranzo C; Ingrosso A; Pratesi G; Lombardi L; Pilotti S; Zunino F
Anticancer Res; 1989; 9(2):361-6. PubMed ID: 2546483
[TBL] [Abstract][Full Text] [Related]
93. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
Sakamoto S; Inoue H; Ohba S; Kohda Y; Usami I; Masuda T; Kawada M; Nomoto A
Cancer Sci; 2015 Apr; 106(4):367-74. PubMed ID: 25640943
[TBL] [Abstract][Full Text] [Related]
94. Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor lines.
Gilbert JA; Frederick LM; Pobst LJ; Ames MM
Biochem Pharmacol; 2005 Apr; 69(8):1159-66. PubMed ID: 15794936
[TBL] [Abstract][Full Text] [Related]
95. Tumor necrosis factor-related apoptosis-inducing ligand modulates angiogenesis and apoptosis to inhibit non-small cell lung carcinoma tumor growth in mice.
Chen Y; Xu Y; Zhu K; Cao Z; Huang Z
J Int Med Res; 2019 Jul; 47(7):3243-3252. PubMed ID: 31234689
[TBL] [Abstract][Full Text] [Related]
96. K252a inhibits the oncogenic properties of Met, the HGF receptor.
Morotti A; Mila S; Accornero P; Tagliabue E; Ponzetto C
Oncogene; 2002 Jul; 21(32):4885-93. PubMed ID: 12118367
[TBL] [Abstract][Full Text] [Related]
97. Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo.
Jiang HL; Jin JZ; Wu D; Xu D; Lin GF; Yu H; Ma DY; Liang J
Mol Biol Rep; 2013 Jul; 40(7):4203-9. PubMed ID: 23649759
[TBL] [Abstract][Full Text] [Related]
98. Inhibition of growth of human small cell lung cancer by bromocriptine.
Ishibashi M; Fujisawa M; Furue H; Maeda Y; Fukayama M; Yamaji T
Cancer Res; 1994 Jul; 54(13):3442-6. PubMed ID: 8012964
[TBL] [Abstract][Full Text] [Related]
99. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines.
Lau PC; Wong EY
Pathol Oncol Res; 2012 Apr; 18(2):357-63. PubMed ID: 21866424
[TBL] [Abstract][Full Text] [Related]
100. A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.
Fujita R; Blot V; Wong E; Stewart C; Lieuw V; Richardson R; Banah A; Villicana J; Timmer A; Coronella J; Newman R; Gymnopoulos M
Cancer Biol Ther; 2020 Jun; 21(6):549-559. PubMed ID: 32192391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
